Contact information
http://www.validate-network.org
CCVTM, University of Oxford, Churchill Hospital, Oxford, OX3 7LE
Research groups
Samantha Vermaak
Executive Manager and Co-Investigator of the VALIDATE vaccine R&D Network
Sam is the Executive Manager and Co-Investigator of the VALIDATE vaccine R&D Network. VALIDATE is an international research network led by Prof Samantha Sampson (Stellenbosch University, South Africa), Prof Helen McShane (University of Oxford, UK), Dr Maria Adelaida Gomez (CIDEIM, Colombia) and Prof Andrea Cooper (University of Leicester, UK), that aims to accelerate vaccine development for three groups of complex neglected intracellular pathogens: mycobacteria (including TB, leprosy and buruli), leishmaniasis, and melioidosis. The network also aims to build capacity in LMICs, connect industry and academia, and facilitate career development for Early Career Researchers, via our many activities, which include providing grants, an Annual Meeting, mentoring, online seminars, and training workshops. VALIDATE membership is free, and VALIDATE follows a One Health and interdisciplinary ethos so welcomes anyone working on any research area that could inform vaccine development for our focus pathogens. We now have over 800 members from more than 75 countries worldwide forming an engaged and interactive community. Find out more about VALIDATE at [http://www.validate-network.org<http://www.validate-network.org/>]www.validate-network.org<http://www.validate-network.org/>.
Previously the Jenner Institute’s TB Vaccine Programme Manager, Sam has extensive experience in project management, research grant management, working with industry partners, managing clinical trials in the UK and overseas, and managing Consortiums. She is also a trained business and personal coach, particularly specialising in supporting the career development of academics. Do get in contact with her for any queries about VALIDATE.
Recent publications
-
The VALIDATE Network: Accelerating Vaccine Development for Tuberculosis, Leishmaniasis, Melioidosis and Leprosy
Vermaak S. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 11 - 25
-
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
-
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
-
A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY
Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369
-
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Wajja A. et al, (2018), Wellcome Open Research, 3, 121 - 121